Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Beilstein J Org Chem ; 17: 156-165, 2021.
Article in English | MEDLINE | ID: mdl-33564326

ABSTRACT

In our hands, efficient access to the 4-amino-3-carboxamide disubstituted pyridine-2(1H)-one kinase hinge-binder motif proved to be more challenging than anticipated requiring a significant investment in route scouting and optimization. This full paper focuses on the synthesis issues that we encountered during our route exploration and the original solutions we found that helped us to identify two optimized library-style processes to prepare our large kinase inhibitor library.

2.
J Med Chem ; 61(9): 4030-4051, 2018 05 10.
Article in English | MEDLINE | ID: mdl-29648825

ABSTRACT

The use of an interleukin ß antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1ß into active IL-1ß, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.


Subject(s)
Acne Vulgaris/drug therapy , Caspase 1/metabolism , Caspase Inhibitors/administration & dosage , Caspase Inhibitors/pharmacology , Drug Design , Acne Vulgaris/enzymology , Administration, Topical , Animals , Caspase 1/chemistry , Caspase Inhibitors/pharmacokinetics , Caspase Inhibitors/therapeutic use , Cell Line , Humans , Mice , Models, Molecular , Protein Conformation , Solvents/chemistry , Tissue Distribution
3.
Bioorg Med Chem Lett ; 27(24): 5373-5377, 2017 12 15.
Article in English | MEDLINE | ID: mdl-29157864

ABSTRACT

Virtual fragmentation of a library of 12,000 compounds inspired by natural products led to a dataset of 153,000 fragments that was used as a source to identify effective P2-P3 scaffold replacement solutions for peptidic Caspase-1 inhibitors. Our strategy led to the identification of an original 2-azabicyclo-octane scaffold (2-ABO) that was further elaborated into the potent Caspase-1 inhibitor CD10847 (IC50 = 17 nM). The crystal structure of Caspase-1 in complex with CD10847 was obtained, and its binding mode was shown to be similar to the one predicted by docking and in good agreement with other known inhibitors.


Subject(s)
4-Butyrolactone/analogs & derivatives , Caspase 1/chemistry , Caspase Inhibitors/chemistry , Dipeptides/chemistry , 4-Butyrolactone/chemical synthesis , 4-Butyrolactone/chemistry , 4-Butyrolactone/metabolism , Azabicyclo Compounds/chemistry , Azabicyclo Compounds/metabolism , Binding Sites , Biological Products/chemistry , Biological Products/metabolism , Caspase 1/metabolism , Caspase Inhibitors/metabolism , Crystallography, X-Ray , Dipeptides/chemical synthesis , Dipeptides/metabolism , Hydrogen Bonding , Inhibitory Concentration 50 , Molecular Conformation , Molecular Docking Simulation , Protein Structure, Tertiary
4.
Dalton Trans ; (1): 250-7, 2006 Jan 07.
Article in English | MEDLINE | ID: mdl-16357983

ABSTRACT

The reactions between Ti(O(i)Pr)(4) and Zr(2)(O(i)Pr)(8)(HO(i)Pr)(2), respectively, and lead 2-ethylhexanoate Pb(O(2)CC(7)H(15))(2) have been investigated at rt and by heating. The initial mixed-metal species, characterized by single-crystal X-Ray diffraction, were adducts namely Pb(4)Zr(4)(mu-O(2)CR')(8)(mu-OR)(6)(mu(3)-OR)(2)(OR)(8)(OHR)(2) and Pb(2)Ti(4)(mu-O(2)CR')(4)(mu-OR)(6)(mu(3)-OR)(2)(OR)(8) (R' = CHCH(Et)C(2)H(4)Me, R = (i)Pr) independently of the stoichiometry used. They are the first Pb-Ti and Pb-Zr non-oxo carboxylatoalkoxides reported. is also the first Pb-Zr species based on an alkoxide-carboxylate ligand set matching the PbZrO(3) stoichiometry. Both structures are centrosymmetric with six-coordinate transition metals, as required for the perovskite, and are based on triangular M(2)Pb cores (M = Zr, Ti). The lead centers display quite high coordination numbers, six and seven. The thermal and hydrolytic condensation reactions of and were investigated. Heat treatment of and elimination of the volatiles under vacuum afforded Pb(2)Ti(3)(mu(4)-O)(mu(3)-O)(mu-O(2)CC(7)H(15))(2)(mu-O(i)Pr)(6)(O(i)Pr)(4) resulting from extrusion of Ti(O(i)Pr)(4) and scrambling of carboxylate ligands. Characterization of the various compounds was achieved by elemental analysis, FT-IR, (1)H and (207)Pb NMR.

SELECTION OF CITATIONS
SEARCH DETAIL
...